A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs RDX 7675 (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Sponsors Ardelyx
- 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
- 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
- 09 Aug 2017 Results from this trial are expected in the fourth quarter of 2017, according to an Ardelyx media release.